ArticleFrontiers in public health2025

An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany.

Ilka Raitner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.